« FIGHTING BACK | Main | Pfizer + Wyeth? »
GERN 5.21,
-0.08,
-1.5%)
said Friday that the U.S. Food and Drug Administration has granted
clearance for it to begin trials for what it said was the world's first
study of a human embryonic stem cell-based therapy for people. Geron
said it will begin a Phase I multicenter trial designed to establish
the safety of its treatment, currently referred to as "GRNOPC1," in
patients with complete Grade A subacute thoracic spinal cord injuries.
Positions: Long Geron Stock
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d834daeb9553ef010536f09a85970c
Listed below are links to weblogs that reference GERON CORP. - HUMAN STEM CELL TEST:
This is only a preview. Your comment has not yet been posted.
As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.
Having trouble reading this image? View an alternate.
Comments